Xiao Jian Zhou

Summary

Affiliation: Idenix Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    J Clin Pharmacol 46:275-81. 2006
  2. pmc Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 50:874-9. 2006
  3. pmc Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:1721-6. 2006
  4. pmc Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:2309-15. 2006
  5. pmc Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 51:4231-5. 2007
  6. doi request reprint Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:725-34. 2009
  7. doi request reprint Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:1408-16. 2009
  8. pmc Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 55:76-81. 2011
  9. pmc Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor
    Steve Piscitelli
    Infectious Diseases MDC, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Br J Clin Pharmacol 74:336-45. 2012
  10. pmc Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 53:1739-46. 2009

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    J Clin Pharmacol 46:275-81. 2006
    ..Results from this study indicated that the absorption of telbivudine was not affected by a high-fat/high-calorie meal; telbivudine can therefore be administered orally with no regard to the timing of meals...
  2. pmc Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 50:874-9. 2006
    ....
  3. pmc Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, 60 Hampshire Street, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:1721-6. 2006
    ....
  4. pmc Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:2309-15. 2006
    ..The results from these studies provide pharmacologic support for combination therapy or therapy switching involving telbivudine, lamivudine, and adefovir dipivoxil for the treatment of chronic hepatitis B virus infection...
  5. pmc Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 51:4231-5. 2007
    ....
  6. doi request reprint Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment
    Xiao Jian Zhou
    Idenix Pharmaceuticals, Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:725-34. 2009
    ....
  7. doi request reprint Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    J Clin Pharmacol 49:1408-16. 2009
    ..IDX899 has been selected based on these initial pharmacokinetic assessments and other criteria as the candidate for further clinical development...
  8. pmc Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 55:76-81. 2011
    ..All AEs were mild to moderate and resolved at the end of study. The favorable safety and pharmacokinetic profiles support further clinical evaluation of IDX184 in HCV-infected patients...
  9. pmc Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor
    Steve Piscitelli
    Infectious Diseases MDC, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Br J Clin Pharmacol 74:336-45. 2012
    ....
  10. pmc Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects
    Xiao Jian Zhou
    Idenix Pharmaceuticals Inc, One Kendall Square, Building 1400, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 53:1739-46. 2009
    ..These favorable safety and pharmacokinetic results support further clinical studies with patients with HIV-1 infection by the use of a QD regimen...
  11. ncbi request reprint Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects
    Pei Hu
    Peking Union Medical College Hospital, Beijing, People s Republic of China
    J Clin Pharmacol 46:999-1007. 2006
    ..4% of the administered dose, with a mean renal clearance of 6.6 L/h. Telbivudine was well tolerated in the studied dose range in healthy Chinese subjects, with no pattern of dose-related clinical or laboratory adverse events...
  12. ncbi request reprint A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection
    Ching Lung Lai
    University of Hong Kong, Hong Kong, China
    Hepatology 40:719-26. 2004
    ..In conclusion, these results support expanded clinical studies of this new agent for the treatment of hepatitis B...
  13. ncbi request reprint 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens
    Omar N Al Safarjalani
    Department of Pharmacology and Toxicology, Comprehensive Cancer Center, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cancer Chemother Pharmacol 55:541-51. 2005
    ..PTAU is fully absorbed after oral administration with 100% oral bioavailability...
  14. pmc Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy
    Rieneke M E van Praag
    National AIDS Therapy Evaluation Center NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, Amsterdam, The Netherlands
    Antimicrob Agents Chemother 46:896-9. 2002
    ..While studies suggest that saquinavir concentrations decrease over time, we show that concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid are stable during 2 years of therapy...